Researchers investigated the protein expression of interleukin (IL)-41 in the synovial tissue of patients with psoriatic arthritis, rheumatoid arthritis, and osteoarthritis and evaluated the production of IL-41 from the enthesis.
Researchers conducted a comparison study of outcomes in patients with psoriatic arthritis treated with secukinumab, apremilast, and other biologic medications.
The study compared the benefits and drug survival of patients with psoriatic arthritis who did not fulfill vs those who did fulfill the inclusion criteria for randomized controlled trials for the TNF inhibitor chosen for their treatment.
The prevalence of neuropathic-like pain was found to be high in patients with psoriatic arthritis, a condition that may be associated with higher disease activity and fibromyalgia.
Inflammation, disease duration, and chronic pain were identified as the main factors underlying fatigue experienced by patients with psoriatic arthritis.
